‫وهناك‬ ‫املتعدد،‬ ‫الت�صلب‬ ‫مر�صى‬ ‫يف‬ ‫إعاقة‬ ‫اال‬ ‫إبطاء‬ ‫ال‬ ‫امل�صتخدمة‬ ‫أدوية‬ ‫اال‬ ‫من‬ ‫اجللتيمرات‬ ‫وا�صيتات‬ ‫انتريفريون‬ ‫البيتا‬ ‫عقاري‬ ‫يعترب‬ ‫امللخ�ص:‬ ‫يف‬ ‫حامل‬ ‫أة‬ ‫أمرا‬ ‫ا‬ ‫م�صيمة‬ ‫يف‬ ‫�صديدة‬ ‫م�صاعفات‬ ‫حدوث‬ ‫عن‬ ‫حالة‬ ‫تقرير‬ ‫هذا‬ ‫احلمل،‬ ‫علي‬ ‫أدوية‬ ‫اال‬ ‫هذه‬ ‫أثري‬ ‫بتا‬ ‫اخلا�صة‬ ‫البيانات‬ ‫يف‬ ‫ت�صارب‬ ‫3102م‬ ‫عام‬ ‫املتحدة‬ ‫العربية‬ ‫إمارات‬ ‫اال‬ ‫يف‬ ‫بالعني‬ ‫توام‬ ‫مل�صت�صفى‬ ‫املري�صة‬ ‫ح�رضت‬ ‫املتعدد،‬ ‫الت�صلب‬ ‫مبر�ض‬ ‫م�صابة‬ ‫العمر‬ ‫من‬ ‫الثالثني‬
During her pregnancy, the patient remained stable; however, a fetal ultrasound at 22 gestational weeks indicated that all fetal growth parameters had decreased. Severe early-onset fetal growth restriction (FGR) was diagnosed. The results of a detailed anatomic survey, karyotyping by amniocentesis and a virology screening test were normal. However, prenatal ultrasonography revealed that the fetus had an echogenic mildly dilated bowel [ Figure 1 ], most probably due to ischaemia. A uterine artery Doppler ultrasound revealed high-resistance flow with early diastolic notching [ Figure 2A ] and an umbilical artery Doppler ultrasound showed absent end-diastolic flow [ Figure 2B ]. Additionally, the patient suffered from oligohydramnios. These findings were suggestive of placental insufficiency as the cause for early-onset FGR. The patient was subsequently monitored with a series of biophysical tests.
At 30 gestational weeks, the patient developed severe pre-eclampsia that was further complicated by HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome. As a result, an emergency Caesarean section was performed and the patient was given full high-intensive care to manage the preeclampsia, including magnesium sulphate infusions, serial monitoring of vitals and renal and respiratory function tests. Post-delivery, the patient had an uneventful recovery and was discharged eight days after the Caesarean section in stable condition with the advice to continue IFN-β as lifelong prophylactic therapy. In this case, the placenta was not sent for histopathology examination; it is recommended to do so in future cases. At birth, the female baby weighed 980 g and was admitted to the Neonatal Unit of Tawam Hospital. A physical examination did not reveal any malformations or abnormalities. The neonate required a postnatal course of surfactant for respiratory distress. She also required total parenteral nutrition initially but subsequently tolerated enteral feeds. She was discharged at the age of two months.
Discussion
There are four clinical types of MS, including relapsing-remitting MS, secondary progressive MS, primary progressive MS and progressive-relapsing MS. Generally, DMDs are recommended for patients who suffer from relapsing forms of MS, such as relapsing-remitting MS or secondary progressive MS with exacerbations; the prescription criteria include abnormal neurological examinations, several MS attacks and a high burden of disease as assessed by magnetic resonance imaging of the brain. 1 The patient in the current case was an ideal candidate for DMDs as she was first diagnosed with relapsing-remitting MS, which then progressed to secondary progressive MS with permanent neurological complications. Hence, she was on lifelong prophylactic therapy with IFN-β 1a. 
Conclusion
This case describes severe placental complications in a pregnant woman with MS who continued taking IFN-β during her first trimester. The continuation of this DMD well into the period of full placental development may have contributed to the development of early-onset FGR and pre-eclampsia in this patient. However, further research into this issue is required to determine whether these factors are related. It is advisable that women who continue taking DMDs during their pregnancies should be followed-up closely to assess and prevent the development of fetal and maternal complications.
In the current case, the patient was prescribed levetriacetam monotherapy to control her epilepsy during pregnancy. With levetriacetam, the risk of major congenital malformations is comparable with that of the non-epileptic population, indicating the relative safety of the drug. 6 On the other hand, a systematic review reported that IFN-β exposure was associated with lower mean birth weight, shorter mean birth length and preterm birth, although the drug was not associated with increased risk of low birth weight infants (<2,500 g), Caesarean section delivery, congenital anomalies or spontaneous abortion. 4 Due to the limited data regarding the effect of DMDs on pregnancy outcomes, women are advised to stop taking the drug either three months or at least one month prior to conception. 7, 8 Close follow-up is recommended for patients who continue taking DMDs during their pregnancies in order to assess and prevent the development of any fetal or maternal complications. Women with MS should be given more education regarding the risks of DMDs in pregnancy.
Extra-villous trophoblast (EVT) cells are fetal cells that invade the mother's uterus, where they transform the spiral arteries into large vessels capable of conducting sufficient blood to the placenta. 9 Early trophoblast invasion is important for placental function and the extent of arterial transformation by the trophoblasts affects successful reproductive outcomes. 9 Severe early-onset FGR overlapping with severe pre-eclampsia, as in the present case, is mainly associated with features of impaired maternal uteroplacental perfusion secondary to defective EVT invasion, which results in insufficient blood supply to the placenta. 10, 11 Placental histopathological findings generally reflect abnormal uteroplacental flow with secondary chronic fetal vasoconstriction and distal villous changes. 11, 12 Trophoblast invasion is controlled by the uterine natural killer cells (uNK cells), the most common uterine leukocyte. 9, 13 The efficacy of IFN-β in patients with MS is due to its immunomodulatory properties; the drug downregulates major histocompatibility molecules on antigen-presenting cells, inhibits proinflammatory cytokine levels, increases regulatory cytokine levels, inhibits T cell proliferation and limits the trafficking of inflammatory cells in the nervous system. 1 These properties evidently oppose the effects of uNK cells. 9, 13 The patient in the current case took IFN-β until the 13 th week of her pregnancy, which is when EVT invasion and placental development occurs. 9 However, further research is required to determine whether DMDs are related to placental insufficiency. Studies using experimental animal models are recommended to assess the relationship between IFN-β and EVT invasion or placental development.
